Orthocell's Remplir™ Shows Remarkable Results in Recent Study
Finding support for the USA sales expansion and EU + UK regulatory applications
- New findings from the Remplir™ study revealed an impressive overall success rate of 81.1% for nerve repair procedures.
- Real World Evidence (RWE) gathered in this study reinforces Orthocell's nerve repair solution, Remplir, as the top choice for uniting severed nerves, safeguarding damaged nerves, or covering nerve ends post-amputation.
-
The findings indicate:
- 83.9% of muscles connected to repaired nerves showed functional motor recovery.
- 89.5% of patients who underwent nerve decompression experienced significant symptom relief or complete resolution.
- No adverse reactions or complications from Remplir were documented in any patient.
- The results align closely with previously released clinical trial data.
- The findings affirm the consistent and reliable outcomes from Remplir, evidenced by the over 200 surgeons in more than 165 hospitals actively using the product.
- This study data will greatly enhance Orthocell's educational outreach for the US market and support the EU + UK regulatory submissions anticipated for late in the year.
- Orthocell is targeting a Global Addressable Market (TAM) exceeding US$3.5 billion.
- Ongoing efforts concentrate on the $1.6 Billion US market, with dedicated teams collaborating with distributors to secure hospital approvals, onboard surgeons, and establish active patient accounts. Initial surgical cases are growing steadily.
The Remplir product represents a strong advancement in regenerative medicine, and the interim results signify Orthocell's commitment to transforming nerve repair practices while enhancing patient experiences. The study results will play a pivotal role in evidence-based education as the company seeks to expand its presence in the US and internationally.
The Impact of Remplir on Nerve Repair Procedures
The Remplir RWE study focused on a wide range of nerve conditions requiring surgical intervention, serving as vital data to bolster both commercial and regulatory efforts. This interim analysis shows how Remplir addresses significant challenges from acute traumatic injuries, chronic nerve conditions, and surgical procedures like carpal tunnel syndrome.
Conducted alongside leading practitioners in the field, the Remplir RWE study generated a wealth of data, illustrating the positive impact on patients dealing with peripheral nerve conditions. With each patient's journey documented, the study reflects a commitment to real-world outcomes and the burgeoning value of RWE in guiding regulatory processes.
Orthocell's CEO, Paul Anderson, emphasized the importance of this data: "We are thrilled with the results from our Remplir RWE Study, affirming the clinical excellence previously published in scholarly journals. The increasing adoption of Remplir by surgical experts reflects the growing demand for effective nerve repair solutions." He further noted, "The data is crucial from both a commercial and regulatory standpoint, showcasing Remplir's performance in diverse patient populations, differing significantly from tightly controlled clinical environments." Additionally, Anderson remarked on the ongoing need for performance data, essential for swift market acceptance in the US and support for regulatory applications in the EU and UK.
Overview of the Remplir RWE Study
This ongoing multi-centre study captures in-depth safety and efficacy assessments of Remplir via both prospective and retrospective analyses in clinical settings. Patients receiving Remplir during various nerve repair procedures are included, aiming to demonstrate its versatility across several conditions.
Patients involved represent a range of ages and backgrounds, dealing with issues stemming from acute nerve injuries or chronic conditions like carpal tunnel syndrome. The comprehensive data collected spans the 24 months post-treatment, focusing on key therapeutic goals such as restoring function or alleviating pain.
Significance of Results and Future Directions
Outcomes reveal a robust success rate, creating a momentum for Orthocell as they aim to lead in the global nerve repair market. As key findings are prepared for presentation at prominent medical conferences, the study moves into deeper phases of patient recruitment and data collection.
The dedication to refining nerve repair standards stands at the forefront of Orthocell's mission, aiming for Remplir to redefine success in restoring functionality to patients worldwide.
Release authorized by: Paul Anderson
CEO and Managing Director of Orthocell Ltd
For further inquiries, please reach out:
Media Contacts:
Haley Chartres
Director, H^CK
Phone: +61 423 139 163
About Orthocell Limited
ACN 118 897 135
Company Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia.
Frequently Asked Questions
What is the main finding of the Remplir™ study?
The study reported an impressive 81.1% overall success rate following nerve repair procedures.
How does the Remplir™ product work?
Remplir is designed to connect severed nerves, protect damaged nerves, and cover nerve ends post-amputation.
What kind of injuries does Remplir™ address?
It targets various peripheral nerve conditions, including acute and chronic injuries such as carpal tunnel syndrome.
Who conducted the Remplir™ study?
The study was conducted alongside leading experts in orthopedic and nerve repair clinics.
What are the future plans for Orthocell and Remplir™?
Orthocell aims to expand its market presence, supported by positive study results, with regulatory submissions planned for the US, UK, and EU.
